Study Review: Harnessing real-world data to inform clinical practice in patients with COVID-19
This review summarises outcomes of three studies that evaluated data obtained from a large US healthcare database to determine the impact of remdesivir treatment of hospitalised patients with COVID-19 in the late Omicron era. The outcomes from these studies demonstrated that treatment of this patient group was associated with a significant reduction in mortality and 30-day readmission risks, especially in the most vulnerable group of patients, namely the elderly and those with immunocompromising conditions. These benefits are of a similar magnitude to those seen during the height of the pandemic.
Expert contributor
Dr Tim Blackmore
Dr Blackmore is based in Wellington where he works as a microbiologist and (occasionally) an infectious diseases physician. He trained in New Zealand and South Australia where he completed fellowships with the RCPA and RACP, and completed a PhD thesis. He is reducing his workload preretirement, concentrating mainly on clinical microbiology.
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.
